Exploring whether genetic perturbation in the gene coding for IL-6 is associated with ASCVD and acceptable safety outcomes could inform investment and development decisions as results from pivotal trials targeting IL-6 are awaited10. The gene discussed is IL6; the disease is atherosclerosis.